Medicare Drug Price Reporting, Preferred Pharmacy Regs Get Makeover In CMS Rule
This article was originally published in The Pink Sheet Daily
Executive Summary
In its proposed rule on Medicare Part D, CMS tackles issues it believes has led to distortions in drug price reporting by plans and a disconnect between drug prices and beneficiary cost-sharing levels.